Literature DB >> 606628

Pathophysiology of hypotension in patients with fulminant hepatic failure.

P N Trewby, R Williams.   

Abstract

Studies on the incidence and pathophysiology of hypotension in fulminant hepatic failure showed that 82 out of 94 patients developed arterial hypotension with a systolic blood pressure of less than 80 mmHg. Such episodes accounted for 16% of the total time spent in grade IV coma. Factors such as haemorrhage, cardiac or respiratory abnormalities, extracorporeal perfusion, or hypotension which occurred during the terminal stages of the illness, could be implicated for only 40% of this time, leaving 60% as unexplained. Further investigation of these unexplained factors showed that peripheral vasodilatation rather than primary heart failure was responsible, and in all but three patients construction of ventricular function curves showed a normal ventricular response to volume expansion with a corresponding increase in blood pressure. A small, but significant, slowing of the heart rate occurred during these periods of unexplained hypotension. This, together with the association that was found between the occurrence of hypotension and cerebral oedema with coning, suggests that central vasomotor depression may be important in its pathogenesis.

Entities:  

Mesh:

Year:  1977        PMID: 606628      PMCID: PMC1411848          DOI: 10.1136/gut.18.12.1021

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  An evaluation of the measurement of the cardiac output and of the so-called pulmonary blood volume by the dye-dilution method.

Authors:  J T DOYLE; J S WILSON; C LEPINE; J V WARREN
Journal:  J Lab Clin Med       Date:  1953-01

Review 2.  Acute hepatic necrosis and fulminant hepatic failure.

Authors:  B Rueff; J P Benhamou
Journal:  Gut       Date:  1973-10       Impact factor: 23.059

Review 3.  Cardiovascular and renal actions of dopamine: potential clinical applications.

Authors:  L I Goldberg
Journal:  Pharmacol Rev       Date:  1972-03       Impact factor: 25.468

Review 4.  Measurement of blood flow by thermodilution.

Authors:  W Ganz; H J Swan
Journal:  Am J Cardiol       Date:  1972-02       Impact factor: 2.778

5.  Charcoal haemoperfusion in the treatment of fulminant hepatic failure.

Authors:  B G Gazzard; M J Weston; I M Murray-Lyon; H Flax; C O Record; R Williams; B Portmann; P G Langley; E H Dunlop; P J Mellon; M B Ward
Journal:  Lancet       Date:  1974-06-29       Impact factor: 79.321

6.  Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure.

Authors:  S P Wilkinson; V Arroyo; B G Gazzard; H Moodie; R Williams
Journal:  Lancet       Date:  1974-03-30       Impact factor: 79.321

7.  Endotoxin-induced liver necrosis and intravascular coagulation in rats enhanced by portacaval collateral circulation.

Authors:  H Liehr; M Grün; H Thiel; D Brunswig; U Rasenack
Journal:  Gut       Date:  1975-06       Impact factor: 23.059

8.  Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis.

Authors:  D B Silk; P N Trewby; R A Chase; P J Mellon; M A Hanid; M Davies; P G Langley; P G Wheeler; R Williams
Journal:  Lancet       Date:  1977-07-02       Impact factor: 79.321

9.  Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage.

Authors:  B G Gazzard; B Portmann; I M Murray-Lyon; R Williams
Journal:  Q J Med       Date:  1975-10

10.  The role of the false neurotransmitter octopamine in the hypotension of fulminant hepatic failure.

Authors:  P N Trewby; R A Chase; M Davis; R Williams
Journal:  Clin Sci Mol Med       Date:  1977-03
View more
  19 in total

1.  Portal hypertension in acute liver failure.

Authors:  M Navasa; J C Garcia-Pagán; J Bosch; J R Riera; R Bañares; A Mas; M Bruguera; J Rodés
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

2.  Changes in brain monoamine metabolism in rats with acute ischemic hepatic failure under artificial cardiopulmonary management.

Authors:  N Murakami; K Saito; T Kato; T Nakamura; U Moriwaki; Y Muto
Journal:  Gastroenterol Jpn       Date:  1992-04

Review 3.  Vasodilatation associated with hepatocellular disease: relation to functional organ failure.

Authors:  S Sherlock
Journal:  Gut       Date:  1990-04       Impact factor: 23.059

4.  Nitric oxide and L-arginine metabolism in a devascularized porcine model of acute liver failure.

Authors:  Vikram Sharma; Gabriella A M Ten Have; Lars Ytrebo; Sambit Sen; Christopher F Rose; R Neil Dalton; Charles Turner; Arthur Revhaug; Hans M H van-Eijk; Nicolaas E P Deutz; Rajiv Jalan; Rajeshwar P Mookerjee; Nathan A Davies
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-15       Impact factor: 4.052

5.  Toxic myocarditis in paracetamol poisoning.

Authors:  E Fagan; A Forbes; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-02

6.  Cerebral oedema and monitoring of intracranial pressure in fulminant hepatic failure.

Authors:  R Ede; A E Gimson; J Cannalese; R Williams
Journal:  Gastroenterol Jpn       Date:  1982-04

7.  Fibronectin and Kupffer cell function in fulminant hepatic failure.

Authors:  M Imawari; R D Hughes; C D Gove; R Williams
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

8.  Hemodynamics and coagulation in experimental auxiliary liver transplantation during fulminant hepatic failure.

Authors:  C B Reuvers; O T Terpstra; T H Groenland; A L Boks; N S Faithfull; F W ten Kate
Journal:  Ann Surg       Date:  1986-11       Impact factor: 12.969

9.  Total hepatectomy and liver transplantation as two-stage procedure.

Authors:  B Ringe; N Lübbe; E Kuse; U Frei; R Pichlmayr
Journal:  Ann Surg       Date:  1993-07       Impact factor: 12.969

10.  Effects of cerebral oedema and arterial hypotension on cerebral blood flow in an animal model of hepatic failure.

Authors:  P N Trewby; M A Hanid; R L Mackenzie; P J Mellon; R Williams
Journal:  Gut       Date:  1978-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.